Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2015

01-12-2015 | NON-THEMATIC REVIEW

Neutrophils: important contributors to tumor progression and metastasis

Authors: Agnieszka Swierczak, Kellie A. Mouchemore, John A. Hamilton, Robin L. Anderson

Published in: Cancer and Metastasis Reviews | Issue 4/2015

Login to get access

Abstract

The presence of neutrophils in tumors has traditionally been considered to be indicative of a failed immune response against cancers. However, there is now evidence showing that neutrophils can promote tumor growth, and increasingly, the data support an active role for neutrophils in tumor progression to distant metastasis. Neutrophils have been implicated in promoting metastasis in cancer patients, where neutrophil numbers and neutrophil-related factors and functions have been associated with progressive disease. Nevertheless, the role of neutrophils in tumors, both at the primary and secondary sites, remains controversial, with some studies reporting their anti-tumor functions. This review will focus on the data demonstrating a role for neutrophils in both tumor growth and metastasis and will attempt to clarify the discrepancies in the literature.
Literature
1.
2.
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.PubMedCrossRef
3.
Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 4(1), 71–78.PubMedCrossRef
4.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology, 66(1), 1–9.PubMedCrossRef
5.
Chee, D. O., Townsend, C. M., Jr., Galbraith, M. A., Eilber, F. R., & Morton, D. L. (1978). Selective reduction of human tumor cell populations by human granulocytes in vitro. Cancer Research, 38(12), 4534–4539.PubMed
6.
Dvorak, A. M., Connell, A. B., Proppe, K., & Dvorak, H. F. (1978). Immunologic rejection of mammary adenocarcinoma (TA3-St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation. Journal of Immunology, 120(4), 1240–1248.
7.
Di Carlo, E., Forni, G., & Musiani, P. (2003). Neutrophils in the antitumoral immune response. Chemical Immunology and Allergy, 83, 182–203.PubMedCrossRef
8.
Souto, J. C., Vila, L., & Bru, A. (2011). Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Medicinal Research Reviews, 31(3), 311–363.PubMedCrossRef
9.
Yan, H. H., Pickup, M., Pang, Y., Gorska, A. E., Li, Z., Chytil, A., et al. (2010). Gr-1 + CD11b + myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Research, 70(15), 6139–6149.PubMedCrossRef
10.
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.PubMedCentralPubMedCrossRef
11.
Colotta, F., Re, F., Polentarutti, N., Sozzani, S., & Mantovani, A. (1992). Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood, 80(8), 2012–2020.PubMed
12.
Smith, J. A. (1994). Neutrophils, host defense, and inflammation: a double-edged sword. Journal of Leukocyte Biology, 56(6), 672–686.PubMed
13.
Ley, K., Laudanna, C., Cybulsky, M. I., & Nourshargh, S. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology, 7(9), 678–689.PubMedCrossRef
14.
Hermant, B., Bibert, S., Concord, E., Dublet, B., Weidenhaupt, M., Vernet, T., et al. (2003). Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. Journal of Biological Chemistry, 278(16), 14002–14012.PubMedCrossRef
15.
Nathan, C. (2006). Neutrophils and immunity: challenges and opportunities. Nature Reviews Immunology, 6(3), 173–182.PubMedCrossRef
16.
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011). Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Reviews Immunology, 11(8), 519–531.PubMedCrossRef
17.
Gabrilovich, D. I., Bronte, V., Chen, S. H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., et al. (2007). The terminology issue for myeloid-derived suppressor cells. Cancer Research, 67(1), 425. author reply 426.PubMedCentralPubMedCrossRef
18.
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., et al. (2000). Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood, 96(12), 3838–3846.PubMedCentralPubMed
19.
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., et al. (2008). Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111(8), 4233–4244.PubMedCrossRef
20.
Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009). Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. Journal of Immunology, 182(1), 240–249.CrossRef
21.
Rieber, N., Gille, C., Köstlin, N., Schäfer, I., Spring, B., Ost, M., et al. (2013). Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. Clinical and Experimental Immunology, 174(1), 45–52.PubMedCentralPubMedCrossRef
22.
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., et al. (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50(3), 799–807.PubMedCrossRef
23.
Cao, Y., Slaney, C. Y., Bidwell, B. N., Parker, B. S., Johnstone, C. N., Rautela, J., et al. (2014). BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Research, 74(18), 5091–5102.PubMedCrossRef
24.
Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research, 68(13), 5439–5449.PubMedCentralPubMedCrossRef
25.
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., et al. (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Research, 64(16), 5839–5849.PubMedCrossRef
26.
Rotondo, R., Barisione, G., Mastracci, L., Grossi, F., Orengo, A. M., Costa, R., et al. (2009). IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. International Journal of Cancer, 125(4), 887–893.CrossRef
27.
Schmielau, J., & Finn, O. J. (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Research, 61(12), 4756–4760.PubMed
28.
Coffelt, S. B., Chen, Y. Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., et al. (2011). Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. Journal of Immunology, 186(7), 4183–4190.CrossRef
29.
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology, 166(1), 678–689.CrossRef
30.
Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., Hwu, P., et al. (1999). Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. Journal of Immunology, 162(10), 5728–5737.
31.
Youn, J. I., Kumar, V., Collazo, M., Nefedova, Y., Condamine, T., Cheng, P., et al. (2013). Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology, 14(3), 211–220.PubMedCentralPubMedCrossRef
32.
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., et al. (2008). Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood, 111(12), 5457–5466.PubMedCrossRef
33.
Youn, J. I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008). Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology, 181(8), 5791–5802.CrossRef
34.
Augier, S., Ciucci, T., Luci, C., Carle, G. F., Blin-Wakkach, C., & Wakkach, A. (2010). Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. Journal of Immunology, 185(12), 7165–7173.CrossRef
35.
Fleming, T. J., Fleming, M. L., & Malek, T. R. (1993). Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. Journal of Immunology, 151(5), 2399–2408.
36.
Rose, S., Misharin, A., & Perlman, H. (2012). A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry. Part A, 81(4), 343–350.CrossRef
37.
Kusmartsev, S., & Gabrilovich, D. I. (2005). STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. Journal of Immunology, 174(8), 4880–4891.CrossRef
38.
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., et al. (2004). Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409–421.PubMedCrossRef
39.
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., et al. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology, 22(2), 238–244.PubMedCrossRef
40.
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., et al. (2010). Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G + Ly6C+ granulocytes. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21248–21255.PubMedCentralPubMedCrossRef
41.
Lenzo, J. C., Turner, A. L., Cook, A. D., Vlahos, R., Anderson, G. P., Reynolds, E. C., et al. (2011). Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunology and Cell Biology, 90(4), 429–40.PubMedCrossRef
42.
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Research, 70(14), 5728–5739.PubMedCrossRef
43.
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011). Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell, 20(3), 300–314.PubMedCentralPubMedCrossRef
44.
Bao, Y., & Cao, X. (2011). Revisiting the protective and pathogenic roles of neutrophils: Ly-6G is key! European Journal of Immunology, 41(9), 2535–2538.PubMedCrossRef
45.
Carr, K. D., Sieve, A. N., Indramohan, M., Break, T. J., Lee, S., & Berg, R. E. (2011). Specific depletion reveals a novel role for neutrophil-mediated protection in the liver during Listeria monocytogenes infection. European Journal of Immunology, 41(9), 2666–2676.PubMedCentralPubMedCrossRef
46.
Bingle, L., Brown, N. J., & Lewis, C. E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology, 196(3), 254–265.PubMedCrossRef
47.
Condeelis, J., & Pollard, J. W. (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124(2), 263–266.PubMedCrossRef
48.
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews, 25(3), 315–322.PubMedCrossRef
49.
Kershaw, M. H., Trapani, J. A., & Smyth, M. J. (1995). Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Therapeutic Immunology, 2(3), 173–181.PubMed
50.
Ghiringhelli, F., Menard, C., Martin, F., & Zitvogel, L. (2006). The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunology Reviews, 214, 229–238.CrossRef
51.
Orentas, R. J., Kohler, M. E., & Johnson, B. D. (2006). Suppression of anti-cancer immunity by regulatory T cells: back to the future. Seminars in Cancer Biology, 16(2), 137–149.PubMedCrossRef
52.
Mougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., & Johansson, C. C. (2010). Regulatory T cells in cancer. Advances in Cancer Research, 107, 57–117.PubMedCrossRef
53.
Draca, S. R. (1993). The participation of natural cytotoxicity in the control of malignant disease. Panminerva Medica, 35(3), 123–126.PubMed
54.
Alderson, K. L., & Sondel, P. M. (2011). Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. Journal of Biomedicine and Biotechnology, 2011, 379123.PubMedCentralPubMedCrossRef
55.
Gillgrass, A., & Ashkar, A. (2011). Stimulating natural killer cells to protect against cancer: recent developments. Expert Review of Clinical Immunology, 7(3), 367–382.PubMedCrossRef
56.
Johnson, G. R., Whitehead, R., & Nicola, N. A. (1985). Effects of a murine mammary tumor on in vivo and in vitro hemopoiesis. International Journal of Cell Cloning, 3(2), 91–105.PubMedCrossRef
57.
Hardy, C. L., & Balducci, L. (1986). Early hematopoietic events during tumor growth in mice. Journal of the National Cancer Institute, 76(3), 535–540.PubMed
58.
Wislez, M., Rabbe, N., Marchal, J., Milleron, B., Crestani, B., Mayaud, C., et al. (2003). Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Research, 63(6), 1405–1412.PubMed
59.
Bellocq, A., Antoine, M., Flahault, A., Philippe, C., Crestani, B., Bernaudin, J. F., et al. (1998). Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. American Journal of Pathology, 152(1), 83–92.PubMedCentralPubMed
60.
Clark, R. A., & Klebanoff, S. J. (1975). Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. Journal of Experimental Medicine, 141(6), 1442–1447.PubMedCrossRef
61.
Kondo, M., Kato, H., Yoshikawa, T., & Sugino, S. (1986). Treatment of cancer ascites by intraperitoneal administration of a streptococcal preparation OK-432 with fresh human complement—role of complement-derived chemotactic factor to neutrophils. International Journal of Immunopharmacology, 8(7), 715–721.PubMedCrossRef
62.
Lichtenstein, A. (1987). Stimulation of the respiratory burst of murine peritoneal inflammatory neutrophils by conjugation with tumor cells. Cancer Research, 47(9), 2211–2217.PubMed
63.
Lichtenstein, A., & Kahle, J. (1985). Anti-tumor effect of inflammatory neutrophils: characteristics of in vivo generation and in vitro tumor cell lysis. International Journal of Cancer, 35(1), 121–127.CrossRef
64.
Pickaver, A. H., Ratcliffe, N. A., Williams, A. E., & Smith, H. (1972). Cytotoxic effects of peritoneal neutrophils on a syngeneic rat tumour. Nature - New Biology, 235(58), 186–187.PubMedCrossRef
65.
Inoue, T., & Sendo, F. (1983). In vitro induction of cytotoxic polymorphonuclear leukocytes by supernatant from a concanavalin A-stimulated spleen cell culture. Journal of Immunology, 131(5), 2508–2514.
66.
Colombo, M. P., Lombardi, L., Stoppacciaro, A., Melani, C., Parenza, M., Bottazzi, B., et al. (1992). Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. Journal of Immunology, 149(1), 113–119.
67.
Musiani, P., Allione, A., Modica, A., Lollini, P. L., Giovarelli, M., Cavallo, F., et al. (1996). Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Laboratory Investigation, 74(1), 146–157.PubMed
68.
Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., et al. (1991). Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. Journal of Experimental Medicine, 173(4), 889–897.PubMedCrossRef
69.
Aeed, P. A., Nakajima, M., & Welch, D. R. (1988). The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells. International Journal of Cancer, 42(5), 748–759.CrossRef
70.
Aeed, P. A., & Welch, D. R. (1988). Sensitivity of locally recurrent rat mammary tumour cell lines to syngeneic polymorphonuclear cell, macrophage and natural killer cell cytolysis. British Journal of Cancer, 58(6), 746–752.PubMedCentralPubMedCrossRef
71.
Dallegri, F., Ballestrero, A., Ottonello, L., & Patrone, F. (1989). Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients. Clinical and Experimental Immunology, 77(1), 58–61.PubMedCentralPubMed
72.
Trellakis, S., Bruderek, K., Dumitru, C. A., Gholaman, H., Gu, X., Bankfalvi, A., et al. (2010). Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. International Journal of Cancer, 129(9), 2183–2193.CrossRef
73.
Tazzyman, S., Barry, S. T., Ashton, S., Wood, P., Blakey, D., Lewis, C. E., et al. (2011). Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. International Journal of Cancer, 129(4), 847–58.CrossRef
74.
Shang, K., Bai, Y. P., Wang, C., Wang, Z., Gu, H. Y., Du, X., et al. (2012). Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One, 7(12), e51848.PubMedCentralPubMedCrossRef
75.
Tazawa, H., Okada, F., Kobayashi, T., Tada, M., Mori, Y., Une, Y., et al. (2003). Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. American Journal of Pathology, 163(6), 2221–2232.PubMedCentralPubMedCrossRef
76.
Ishikawa, M., Koga, Y., Hosokawa, M., & Kobayashi, H. (1986). Augmentation of B16 melanoma lung colony formation in C57BL/6 mice having marked granulocytosis. International Journal of Cancer, 37(6), 919–924.CrossRef
77.
Jung, M. R., Park, Y. K., Jeong, O., Seon, J. W., Ryu, S. Y., Kim, D. Y., et al. (2011). Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. Journal of Surgical Oncology, 104(5), 504–510.PubMedCrossRef
78.
Shimada, H., Takiguchi, N., Kainuma, O., Soda, H., Ikeda, A., Cho, A., et al. (2010). High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer, 13(3), 170–176.PubMedCrossRef
79.
Ubukata, H., Konishi, S., Nagata, H., Kasuga, N., Watanabe, Y., Goto, Y., et al. (2010). Significance of preoperative evaluations of tumor necrosis factor-alpha, the granulocyte/lymphocyte ratio and their correlation with regard to outcome in gastric cancer patients. Digestive Surgery, 27(4), 324–330.PubMedCrossRef
80.
Ding, P. R., An, X., Zhang, R. X., Fang, Y. J., Li, L. R., Chen, G., et al. (2010). Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. International Journal of Colorectal Disease, 25(12), 1427–1433.PubMedCrossRef
81.
Roxburgh, C. S., Wallace, A. M., Guthrie, G. K., Horgan, P. G., & McMillan, D. C. (2010). Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative surgery for colon cancer. Colorectal Disease, 12(10), 987–994.PubMedCrossRef
82.
Chua, W., Charles, K. A., Baracos, V. E., & Clarke, S. J. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer, 104(8), 1288–1295.PubMedCentralPubMedCrossRef
83.
Tomita, M., Shimizu, T., Ayabe, T., Yonei, A., & Onitsuka, T. (2011). Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Research, 31(9), 2995–2998.PubMed
84.
Sharaiha, R. Z., Halazun, K. J., Mirza, F., Port, J. L., Lee, P. C., Neugut, A. I., et al. (2011). Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Annals of Surgical Oncology, 18(12), 3362–9.PubMedCentralPubMedCrossRef
85.
Aliustaoglu, M., Bilici, A., Seker, M., Dane, F., Gocun, M., Konya, V., et al. (2010). The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepato-Gastroenterology, 57(99–100), 640–645.PubMed
86.
An, X., Ding, P. R., Li, Y. H., Wang, F. H., Shi, Y. X., Wang, Z. Q., et al. (2010). Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers, 15(6), 516–522.PubMedCrossRef
87.
Bhatti, I., Peacock, O., Lloyd, G., Larvin, M., & Hall, R. I. (2010). Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. American Journal of Surgery, 200(2), 197–203.PubMedCrossRef
88.
Tavares-Murta, B. M., Mendonca, M. A., Duarte, N. L., da Silva, J. A., Mutao, T. S., Garcia, C. B., et al. (2010). Systemic leukocyte alterations are associated with invasive uterine cervical cancer. International Journal of Gynecological Cancer, 20(7), 1154–1159.PubMedCrossRef
89.
Cho, H., Hur, H. W., Kim, S. W., Kim, S. H., Kim, J. H., Kim, Y. T., et al. (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunology, Immunotherapy, 58(1), 15–23.PubMedCrossRef
90.
Thavaramara, T., Phaloprakarn, C., Tangjitgamol, S., & Manusirivithaya, S. (2011). Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. Journal of the Medical Association of Thailand, 94(7), 871–877.PubMed
91.
Yamashita, J., Ogawa, M., & Shirakusa, T. (1995). Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. Journal of Leukocyte Biology, 57(3), 375–378.PubMed
92.
Jensen, H. K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F., & von der Maase, H. (2009). Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. Journal of Clinical Oncology, 27(28), 4709–4717.PubMedCrossRef
93.
Kuang, D. M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., et al. (2011). Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of Hepatology, 54(5), 948–955.PubMedCrossRef
94.
Mentzel, T., Brown, L. F., Dvorak, H. F., Kuhnen, C., Stiller, K. J., Katenkamp, D., et al. (2001). The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Archiv, 438(1), 13–22.PubMedCrossRef
95.
Jensen, T. O., Schmidt, H., Moller, H. J., Donskov, F., Hoyer, M., & Sjoegren, P. (2011). Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer, 118(9), 2476–8.PubMedCrossRef
96.
Liu, H., Ubukata, H., Tabuchi, T., Takemura, A., Motohashi, G., Nishimura, M., et al. (2009). It is possible that tumour-infiltrating granulocytes promote tumour progression. Oncology Reports, 22(1), 29–33.PubMed
97.
98.
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell, 16(3), 183–194.PubMedCentralPubMedCrossRef
99.
Mantovani, A., Sica, A., & Locati, M. (2005). Macrophage polarization comes of age. Immunity, 23(4), 344–346.PubMedCrossRef
100.
Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S., & Weiss, S. (2010). Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. Journal of Clinical Investigation, 120(4), 1151–1164.PubMedCentralPubMedCrossRef
101.
Houghton, A. M. (2010). The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle, 9(9), 1732–1737.PubMedCrossRef
102.
Mishalian, I., Bayuh, R., Levy, L., Zolotarov, L., Michaeli, J., & Fridlender, Z. G. (2013). Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunology, Immunotherapy, 62(11), 1745–1756.PubMedCrossRef
103.
Wu, Q. D., Wang, J. H., Condron, C., Bouchier-Hayes, D., & Redmond, H. P. (2001). Human neutrophils facilitate tumor cell transendothelial migration. American Journal of Physiology - Cellular Physiology, 280(4), C814–822.
104.
Wislez, M., Fleury-Feith, J., Rabbe, N., Moreau, J., Cesari, D., Milleron, B., et al. (2001). Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma. American Journal of Pathology, 159(4), 1423–1433.PubMedCentralPubMedCrossRef
105.
Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539–545.PubMedCrossRef
106.
Hannelien, V., Karel, G., Jo, V. D., & Sofie, S. (2011). The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochimica et Biophysica Acta, 1825(1), 117–129.PubMed
107.
Murdoch, C., & Finn, A. (2000). Chemokine receptors and their role in inflammation and infectious diseases. Blood, 95(10), 3032–3043.PubMed
108.
Waugh, D. J., & Wilson, C. (2008). The interleukin-8 pathway in cancer. Clinical Cancer Research, 14(21), 6735–6741.PubMedCrossRef
109.
Eck, M., Schmausser, B., Scheller, K., Brandlein, S., & Muller-Hermelink, H. K. (2003). Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clinical and Experimental Immunology, 134(3), 508–515.PubMedCentralPubMedCrossRef
110.
Bieche, I., Chavey, C., Andrieu, C., Busson, M., Vacher, S., Le Corre, L., et al. (2007). CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocrine-Related Cancer, 14(4), 1039–1052.PubMedCrossRef
111.
Cheng, W. L., Wang, C. S., Huang, Y. H., Tsai, M. M., Liang, Y., & Lin, K. H. (2011). Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Annals of Oncology, 22(10), 2267–2276.PubMedCrossRef
112.
Strell, C., Lang, K., Niggemann, B., Zaenker, K. S., & Entschladen, F. (2010). Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Experimental Cell Research, 316(1), 138–148.PubMedCrossRef
113.
di Celle, P. F., Carbone, A., Marchis, D., Zhou, D., Sozzani, S., Zupo, S., et al. (1994). Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood, 84(1), 220–228.PubMed
114.
Green, A. R., Green, V. L., White, M. C., & Speirs, V. (1997). Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. International Journal of Cancer, 72(6), 937–941.CrossRef
115.
Tjiong, M. Y., van der Vange, N., ten Kate, F. J., Tjong, A. H. S. P., ter Schegget, J., Burger, M. P., et al. (1999). Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecologic Oncology, 73(2), 285–291.PubMedCrossRef
116.
Scheibenbogen, C., Mohler, T., Haefele, J., Hunstein, W., & Keilholz, U. (1995). Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Research, 5(3), 179–181.PubMedCrossRef
117.
Haqqani, A. S., Sandhu, J. K., & Birnboim, H. C. (2000). Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia, 2(6), 561–568.PubMedCentralPubMedCrossRef
118.
Schaider, H., Oka, M., Bogenrieder, T., Nesbit, M., Satyamoorthy, K., Berking, C., et al. (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. International Journal of Cancer, 103(3), 335–343.CrossRef
119.
Yao, C., Lin, Y., Chua, M. S., Ye, C. S., Bi, J., Li, W., et al. (2007). Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. International Journal of Cancer, 121(9), 1949–1957.CrossRef
120.
Maus, U. A., Waelsch, K., Kuziel, W. A., Delbeck, T., Mack, M., Blackwell, T. S., et al. (2003). Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. Journal of Immunology, 170(6), 3273–3278.CrossRef
121.
Vlodavsky, I., Fuks, Z., Ishai-Michaeli, R., Bashkin, P., Levi, E., Korner, G., et al. (1991). Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. Journal of Cellular Biochemistry, 45(2), 167–176.PubMedCrossRef
122.
123.
Lawrence, M. B., & Springer, T. A. (1993). Neutrophils roll on E-selectin. Journal of Immunology, 151(11), 6338–6346.
124.
Woodfin, A., Voisin, M. B., & Nourshargh, S. (2010). Recent developments and complexities in neutrophil transmigration. Current Opinion in Hematology, 17(1), 9–17.PubMedCentralPubMedCrossRef
125.
Opdenakker, G., & Van Damme, J. (2004). The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. International Journal of Developmental Biology, 48(5–6), 519–527.PubMedCrossRef
126.
Piccard, H., Muschel, R. J., & Opdenakker, G. (2012). On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Critical Reviews in Oncology/Hematology, 82(3), 296–309.PubMedCrossRef
127.
Pham, C. T. (2006). Neutrophil serine proteases: specific regulators of inflammation. Nature Reviews Immunology, 6(7), 541–550.PubMedCrossRef
128.
Hager, M., Cowland, J. B., & Borregaard, N. (2010). Neutrophil granules in health and disease. Journal of Internal Medicine, 268(1), 25–34.PubMed
129.
Belaaouaj, A., McCarthy, R., Baumann, M., Gao, Z., Ley, T. J., Abraham, S. N., et al. (1998). Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nature Medicine, 4(5), 615–618.PubMedCrossRef
130.
Lee, W. L., & Downey, G. P. (2001). Leukocyte elastase: physiological functions and role in acute lung injury. American Journal of Respiratory and Critical Care Medicine, 164(5), 896–904.PubMedCrossRef
131.
Houghton, A. M., Rzymkiewicz, D. M., Ji, H., Gregory, A. D., Egea, E. E., Metz, H. E., et al. (2010). Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine, 16(2), 219–223.PubMedCentralPubMedCrossRef
132.
Wada, Y., Yoshida, K., Hihara, J., Konishi, K., Tanabe, K., Ukon, K., et al. (2006). Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Science, 97(10), 1037–1043.PubMedCrossRef
133.
Gong, L., Cumpian, A. M., Caetano, M. S., Ochoa, C. E., De la Garza, M. M., Lapid, D. J., et al. (2013). Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Molecular Cancer, 12(1), 154.PubMedCentralPubMedCrossRef
134.
Clavel, C., Polette, M., Doco, M., Binninger, I., & Birembaut, P. (1992). Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bulletin du Cancer, 79(3), 261–270.PubMed
135.
Hojilla, C. V., Wood, G. A., & Khokha, R. (2008). Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Research, 10(2), 205.PubMedCentralPubMedCrossRef
136.
137.
Nielsen, B. S., Timshel, S., Kjeldsen, L., Sehested, M., Pyke, C., Borregaard, N., et al. (1996). 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. International Journal of Cancer, 65(1), 57–62.CrossRef
138.
Nozawa, H., Chiu, C., & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12493–12498.PubMedCentralPubMedCrossRef
139.
Bausch, D., Pausch, T., Krauss, T., Hopt, U. T., Fernandez-del-Castillo, C., Warshaw, A. L., et al. (2011). Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis, 14(3), 235–243.PubMedCentralPubMedCrossRef
140.
Bekes, E. M., Schweighofer, B., Kupriyanova, T. A., Zajac, E., Ardi, V. C., Quigley, J. P., et al. (2011). Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. American Journal of Pathology, 179(3), 1455–1470.PubMedCentralPubMedCrossRef
141.
Nakamura, T., Kuwai, T., Kim, J. S., Fan, D., Kim, S. J., & Fidler, I. J. (2007). Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia, 9(11), 979–986.PubMedCentralPubMedCrossRef
142.
Starkey, J. R., Liggitt, H. D., Jones, W., & Hosick, H. L. (1984). Influence of migratory blood cells on the attachment of tumor cells to vascular endothelium. International Journal of Cancer, 34(4), 535–543.CrossRef
143.
Huh, S. J., Liang, S., Sharma, A., Dong, C., & Robertson, G. P. (2010). Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Research, 70(14), 6071–6082.PubMedCentralPubMedCrossRef
144.
Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407(6801), 249–257.PubMedCrossRef
145.
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29(6 Suppl 16), 15–18.PubMedCrossRef
146.
Cassatella, M. A. (1999). Neutrophil-derived proteins: selling cytokines by the pound. Advances in Immunology, 73, 369–509.PubMedCrossRef
147.
Benelli, R., Albini, A., & Noonan, D. (2003). Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. Chemical Immunology and Allergy, 83, 167–181.PubMedCrossRef
148.
Scapini, P., Morini, M., Tecchio, C., Minghelli, S., Di Carlo, E., Tanghetti, E., et al. (2004). CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. Journal of Immunology, 172(8), 5034–5040.CrossRef
149.
Van Coillie, E., Van Aelst, I., Wuyts, A., Vercauteren, R., Devos, R., De Wolf-Peeters, C., et al. (2001). Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. American Journal of Pathology, 159(4), 1405–1414.PubMedCentralPubMedCrossRef
150.
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103(3), 481–490.PubMedCentralPubMedCrossRef
151.
Coussens, L. M., & Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chemical Biology, 3(11), 895–904.CrossRef
152.
Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3(6), 401–410.PubMedCrossRef
153.
Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2(3), 161–174.PubMedCrossRef
154.
Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., et al. (2001). Gelatinase B functions as regulator and effector in leukocyte biology. Journal of Leukocyte Biology, 69(6), 851–859.PubMed
155.
Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I., & Quigley, J. P. (2007). Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(51), 20262–20267.PubMedCentralPubMedCrossRef
156.
Deryugina, E. I., Zajac, E., Juncker-Jensen, A., Kupriyanova, T. A., Welter, L., & Quigley, J. P. (2014). Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia, 16(10), 771–788.PubMedCentralPubMedCrossRef
157.
Morikawa, K., Kamegaya, S., Yamazaki, M., & Mizuno, D. (1985). Hydrogen peroxide as a tumoricidal mediator of murine polymorphonuclear leukocytes induced by a linear beta-1,3-D-glucan and some other immunomodulators. Cancer Research, 45(8), 3482–3486.PubMed
158.
Lambeth, J. D. (2004). NOX enzymes and the biology of reactive oxygen. Nature Reviews Immunology, 4(3), 181–189.PubMedCrossRef
159.
Babior, B. M., Lambeth, J. D., & Nauseef, W. (2002). The neutrophil NADPH oxidase. Archives of Biochemistry and Biophysics, 397(2), 342–344.PubMedCrossRef
160.
Fialkow, L., Wang, Y., & Downey, G. P. (2007). Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radical Biology and Medicine, 42(2), 153–164.PubMedCrossRef
161.
Evans, T. J., Buttery, L. D., Carpenter, A., Springall, D. R., Polak, J. M., & Cohen, J. (1996). Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. Proceedings of the National Academy of Sciences of the United States of America, 93(18), 9553–9558.PubMedCentralPubMedCrossRef
162.
Wheeler, M. A., Smith, S. D., Garcia-Cardena, G., Nathan, C. F., Weiss, R. M., & Sessa, W. C. (1997). Bacterial infection induces nitric oxide synthase in human neutrophils. Journal of Clinical Investigation, 99(1), 110–116.PubMedCentralPubMedCrossRef
163.
Sandhu, J. K., Privora, H. F., Wenckebach, G., & Birnboim, H. C. (2000). Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model. American Journal of Pathology, 156(2), 509–518.PubMedCentralPubMedCrossRef
164.
Weitzman, S. A., & Gordon, L. I. (1990). Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood, 76(4), 655–663.PubMed
165.
Wilkinson, D., Sandhu, J. K., Breneman, J. W., Tucker, J. D., & Birnboim, H. C. (1995). Hprt mutants in a transplantable murine tumour arise more frequently in vivo than in vitro. British Journal of Cancer, 72(5), 1234–1240.PubMedCentralPubMedCrossRef
166.
Tamir, S., & Tannenbaum, S. R. (1996). The role of nitric oxide (NO.) in the carcinogenic process. Biochimica et Biophysica Acta, 1288(2), F31–36.PubMed
167.
Knaapen, A. M., Gungor, N., Schins, R. P., Borm, P. J., & Van Schooten, F. J. (2006). Neutrophils and respiratory tract DNA damage and mutagenesis: a review. Mutagenesis, 21(4), 225–236.PubMedCrossRef
168.
Bronte, V., & Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology, 5(8), 641–654.PubMedCrossRef
169.
170.
Roy, L. D., Ghosh, S., Pathangey, L. B., Tinder, T. L., Gruber, H. E., & Mukherjee, P. (2011). Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer, 11, 365.PubMedCentralPubMedCrossRef
171.
172.
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., et al. (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell, 13(1), 23–35.PubMedCentralPubMedCrossRef
173.
De Larco, J. E., Wuertz, B. R., & Furcht, L. T. (2004). The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer Research, 10(15), 4895–4900.PubMedCrossRef
174.
Welch, D. R., Schissel, D. J., Howrey, R. P., & Aeed, P. A. (1989). Tumor-elicited polymorphonuclear cells, in contrast to “normal” circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 86(15), 5859–5863.PubMedCentralPubMedCrossRef
175.
Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F., & Honn, K. V. (1985). Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Laboratory Investigation, 53(4), 470–478.PubMed
176.
Dong, C., Slattery, M. J., Liang, S., & Peng, H. H. (2005). Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Molecular & Cellular Biomechanics, 2(3), 145–159.
177.
Slattery, M. J., & Dong, C. (2003). Neutrophils influence melanoma adhesion and migration under flow conditions. International Journal of Cancer, 106(5), 713–722.CrossRef
178.
Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., et al. (2014). Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell, 158(5), 1110–1122.PubMedCentralPubMedCrossRef
179.
Liotta, L. A., Saidel, M. G., & Kleinerman, J. (1976). The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Research, 36(3), 889–894.PubMed
180.
Morimoto-Kamata, R., Mizoguchi, S., Ichisugi, T., & Yui, S. (2012). Cathepsin G induces cell aggregation of human breast cancer MCF-7 cells via a 2-step mechanism: catalytic site-independent binding to the cell surface and enzymatic activity-dependent induction of the cell aggregation. Mediators of Inflammation, 2012, 456462.PubMedCentralPubMedCrossRef
181.
Yui, S., Tomita, K., Kudo, T., Ando, S., & Yamazaki, M. (2005). Induction of multicellular 3-D spheroids of MCF-7 breast carcinoma cells by neutrophil-derived cathepsin G and elastase. Cancer Science, 96(9), 560–570.PubMedCrossRef
182.
Acuff, H. B., Carter, K. J., Fingleton, B., Gorden, D. L., & Matrisian, L. M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Research, 66(1), 259–266.PubMedCentralPubMedCrossRef
183.
Fox, S., Leitch, A. E., Duffin, R., Haslett, C., & Rossi, A. G. (2010). Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. Journal of Innate Immunity, 2(3), 216–227.PubMedCentralPubMedCrossRef
184.
Filardy, A. A., Pires, D. R., Nunes, M. P., Takiya, C. M., Freire-de-Lima, C. G., Ribeiro-Gomes, F. L., et al. (2010). Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages. Journal of Immunology, 185(4), 2044–2050.CrossRef
185.
Broug-Holub, E., Toews, G. B., van Iwaarden, J. F., Strieter, R. M., Kunkel, S. L., Paine, R., 3rd, et al. (1997). Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infection and Immunity, 65(4), 1139–1146.PubMedCentralPubMed
186.
Pahler, J. C., Tazzyman, S., Erez, N., Chen, Y. Y., Murdoch, C., Nozawa, H., et al. (2008). Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia, 10(4), 329–340.PubMedCentralPubMedCrossRef
187.
Silva, M. T. (2011). Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation. Journal of Leukocyte Biology, 89(5), 675–683.PubMedCrossRef
188.
Allenbach, C., Zufferey, C., Perez, C., Launois, P., Mueller, C., & Tacchini-Cottier, F. (2006). Macrophages induce neutrophil apoptosis through membrane TNF, a process amplified by Leishmania major. Journal of Immunology, 176(11), 6656–6664.CrossRef
189.
Swierczak, A., Cook, A. D., Lenzo, J. C., Restall, C. M., Doherty, J. P., Anderson, R. L., et al. (2014). The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunology Research, 2(8), 765–776.PubMedCrossRef
190.
Denardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1, 54–67.PubMedCentralPubMedCrossRef
191.
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 25(6), 846–859.PubMedCrossRef
192.
Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., & Ley, K. (2010). Development of monocytes, macrophages, and dendritic cells. Science, 327(5966), 656–661.PubMedCentralPubMedCrossRef
193.
Borregaard, N., & Cowland, J. B. (1997). Granules of the human neutrophilic polymorphonuclear leukocyte. Blood, 89(10), 3503–3521.PubMed
194.
Tazzyman, S., Lewis, C. E., & Murdoch, C. (2009). Neutrophils: key mediators of tumour angiogenesis. International Journal of Experimental Pathology, 90(3), 222–231.PubMedCentralPubMedCrossRef
195.
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D., & Strieter, R. M. (1996). Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Journal of Clinical Investigation, 97(12), 2792–2802.PubMedCentralPubMedCrossRef
196.
Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X. D., et al. (2002). Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. American Journal of Pathology, 161(1), 125–134.PubMedCentralPubMedCrossRef
197.
Walters, I., Austin, C., Austin, R., Bonnert, R., Cage, P., Christie, M., et al. (2008). Evaluation of a series of bicyclic CXCR2 antagonists. Bioorganic and Medicinal Chemistry Letters, 18(2), 798–803.PubMedCrossRef
198.
Varney, M. L., Singh, S., Li, A., Mayer-Ezell, R., Bond, R., & Singh, R. K. (2011). Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Letters, 300(2), 180–188.PubMedCentralPubMedCrossRef
199.
Singh, S., Sadanandam, A., Nannuru, K. C., Varney, M. L., Mayer-Ezell, R., Bond, R., et al. (2009). Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clinical Cancer Research, 15(7), 2380–2386.PubMedCentralPubMedCrossRef
200.
Ning, Y., Labonte, M. J., Zhang, W., Bohanes, P. O., Gerger, A., Yang, D., et al. (2012). The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular Cancer Therapeutics, 11(6), 1353–1364.PubMedCrossRef
201.
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C. S., et al. (2015). IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 522(7556), 345–8.PubMedCrossRef
202.
Gadducci, A., Sergiampietri, C., & Guiggi, I. (2013). Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecological Endocrinology, 29(9), 811–6.PubMedCrossRef
203.
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., et al. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6742–6747.PubMedCentralPubMedCrossRef
204.
Phan, V. T., Wu, X., Cheng, J. H., Sheng, R. X., Chung, A. S., Zhuang, G., et al. (2013). Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proceedings of the National Academy of Sciences of the United States of America, 110(15), 6079–6084.PubMedCentralPubMedCrossRef
205.
Shojaei, F., & Ferrara, N. (2008). Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Research, 68(14), 5501–5504.PubMedCrossRef
206.
Sanford, M. A., Yan, Y., Canfield, S. E., Hassan, W., Selleck, W. A., Atkinson, G., et al. (2001). Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer. Human Gene Therapy, 12(12), 1485–1498.PubMedCrossRef
207.
Siders, W. M., Shields, J., Garron, C., Hu, Y., Boutin, P., Shankara, S., et al. (2010). Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia and Lymphoma, 51(7), 1293–1304.PubMedCrossRef
208.
Hernandez-Ilizaliturri, F. J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A., Repasky, E., et al. (2003). Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research, 9(16 Pt 1), 5866–5873.PubMed
209.
Thornton, L. M., Andersen, B. L., & Carson, W. E., 3rd. (2008). Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case–control analysis. Cancer Immunology, Immunotherapy, 57(10), 1471–1481.PubMedCentralPubMedCrossRef
210.
Fridlender, Z. G., & Albelda, S. M. (2012). Tumor-associated neutrophils: friend or foe? Carcinogenesis, 33(5), 949–955.PubMedCrossRef
211.
Remedi, M. M., Donadio, A. C., & Chiabrando, G. A. (2009). Polymorphonuclear cells stimulate the migration and metastatic potential of rat sarcoma cells. International Journal of Experimental Pathology, 90(1), 44–51.PubMedCentralPubMedCrossRef
Metadata
Title
Neutrophils: important contributors to tumor progression and metastasis
Authors
Agnieszka Swierczak
Kellie A. Mouchemore
John A. Hamilton
Robin L. Anderson
Publication date
01-12-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9594-9

Other articles of this Issue 4/2015

Cancer and Metastasis Reviews 4/2015 Go to the issue

NON-THEMATIC REVIEW

The origin of prostate metastases: emerging insights

CLINICAL

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

CLINICAL

New advances in ovarian autotransplantation to restore fertility in cancer patients

NON-THEMATIC REVIEW

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

NON-THEMATIC REVIEW

Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer

NON-THEMATIC REVIEW

Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits